AAV-ApoA4

AAV-ApoA4 is an adeno-associated virus (AAV) vector-based gene therapy designed to overexpress Apolipoprotein A-IV (ApoA4). ApoA4 is a protein primarily secreted by the intestine that plays a role in lipid metabolism, glucose homeostasis, and anti-atherosclerosis. In preclinical models of nonalcoholic steatohepatitis (NASH) and diet-induced obesity, AAV-ApoA4 delivery has been shown to regulate lipid trafficking from the liver to adipose tissue. Specifically, it promotes hepatic lipolysis while inhibiting lipolysis and enhancing lipogenesis in white and brown adipose tissues, effectively redirecting fat for energy metabolism and reducing hepatic steatosis. The therapy aims to restore metabolic balance by modulating key enzymes such as ATGL, ACC, and SCD1, and enhancing thermogenic pathways involving SIRT1, PGC1, and UCP1.

Other names

Adeno-associated virus-Apolipoprotein A-IV